Pete Stavropoulos

“Looking forward to the data next month, and thanks for taking our questions. A couple from me.”

“For the phase three approach study, what are some of the tools or mechanisms you've put in place to ensure clinical site quality and execution, screening process for enrollment to ensure you're enrolling real MDD patients and avoiding professional patients?”

“In the slide there, just for clarity, in the slide deck for regulatory and clinical plan, And it says advance the phase two into pediatric study in the second half of next year, ages zero to six.”

“Congratulations on the updates and progress for the quarter, and thank you for taking our questions. One question is whether you have targeted engagement when dosing humans in PMN 310.”

“Good morning and congratulations on the progress and thank you for taking our questions um my question uh is around the clinical program on bp205 um congrats on the sad data uh good good first step um and uh i'm curious on how the short team match uh relatively long half-life and high potency uh could translate into a…”